Seward & Kissel advises Amblyotech, Inc. on its Sale to Novartis

May 20, 2020

On April 20, 2020, Amblyotech, Inc. announced the completion of its sale to Novartis. Seward & Kissel was pleased to represent Amblyotech in connection with this middle-market M&A transaction.

Amblyotech is an Arizona-based company that is developing active and passive video therapies to treat amblyopia (“lazy eye”). Novartis is a leading global medicines company based in Basel, Switzerland.

Seward & Kissel LLP ( is a leading New York law firm, originally established in 1890, offering legal advice emphasizing business, financial and commercial law and related litigation. The firm’s Business Transactions Group handles middle-market M&A, private equity, venture capital and joint venture transactions involving a wide variety of industries. The firm is ranked as Highly Regarded for Corporate/M&A by Chambers USA and is recommended by The Legal 500 in the middle-market M&A category, stating that Seward & Kissel “advises on market-leading transactions within the industries where the firm has an international reputation, namely investment management and shipping” and “also handles complex middle-market deals in the media industry and international sell-side M&A.”

Amblyotech’s press release describing this transaction can be viewed by clicking here and Novartis’ press release describing this transaction can be viewed by clicking here.